<DOC>
	<DOCNO>NCT00000644</DOCNO>
	<brief_summary>This study design evaluate efficacy safety clarithromycin give orally 1 3 dos treat disseminate Mycobacterium avium complex infection ( MAC ) patient AIDS . Mycobacterium avium complex ( MAC ) think common disseminated bacterial opportunistic infection AIDS , clinical prevalence estimate range 15 50 percent AIDS patient . Clarithromycin , new macrolide antimicrobial agent , demonstrate activity MAC laboratory animal . Clinical experience treat AIDS patient clarithromycin disseminate MAC limit . However , early study indicate adverse effect improvement clinical symptom score Karnofsky performance score placebo treat patient .</brief_summary>
	<brief_title>A Phase II Safety Efficacy Study Clarithromycin Treatment Disseminated M. Avium Complex ( MAC ) Infections Patients With AIDS</brief_title>
	<detailed_description>Mycobacterium avium complex ( MAC ) think common disseminated bacterial opportunistic infection AIDS , clinical prevalence estimate range 15 50 percent AIDS patient . Clarithromycin , new macrolide antimicrobial agent , demonstrate activity MAC laboratory animal . Clinical experience treat AIDS patient clarithromycin disseminate MAC limit . However , early study indicate adverse effect improvement clinical symptom score Karnofsky performance score placebo treat patient . Treatment randomly assign twice many patient receive clarithromycin low dose intermediate dose 12 week . Once data becomes available support dose patient clarithromycin high dose , treatment randomly assign twice many patient receive clarithromycin high dose intermediate dose . Sixteen patient per group ( 48 patient ) enrol . Patients exhibit clinical improvement clinical cure trial allow continue therapy additional 6 month . Patients clinical evaluation ( include Karnofsky Performance Scale ) , laboratory evaluation ( hematology chemistry ) , blood culture MAC perform monthly .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Didanosine ( ddI ) . Dideoxycytidine ( ddC ) . Zidovudine ( AZT ) . Acetaminophen . Acyclovir . Fluconazole . Erythropoietin ( EPO ) . Systemic Pneumocystis carinii pneumonia ( PCP ) prophylaxis ( aerosolized oral pentamidine , trimethoprim / sulfamethoxazole , dapsone ) . Maintenance ganciclovir therapy ( permit dose clinical laboratory parameter stable least 4 week prior study entry ) . Maintenance treatment opportunistic infection dose clinical laboratory parameter stable 4 week prior study entry . Patients must : Positive result HIV ELISA confirm another method . Positive blood culture Mycobacterium avium complex within 2 month study entry clinical symptom MAC infection . Discontinued mycobacterial drug ( approve investigational ) least 4 week prior start drug therapy ( exception isoniazid prophylaxis discontinue Study Day minus 14 Study Day minus 7 Given write informed consent participate trial . Met list laboratory parameter pretreatment visit . Prior Medication : Allowed : Didanosine ( ddI ) . Deoxycytidine ( ddC ) . Zidovudine ( AZT ) . Acetaminophen . Acyclovir . Fluconazole . Erythropoietin ( EPO ) . Systemic Pneumocystis carinii pneumonia ( PCP ) prophylaxis ( aerosolized oral pentamidine , dapsone , trimethoprim / sulfamethoxazole ) . Maintenance ganciclovir therapy ( permit dose clinical laboratory parameter stable least 4 week prior study entry ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection . Maintenance treatment opportunistic infection permit dose clinical laboratory parameter stable 4 week prior study entry . Concurrent Medication : Excluded : Aminoglycosides . Ansamycin ( rifabutin ) . Quinolones . Other macrolides . Clofazimine . Cytotoxic chemotherapy . Rifampin . Ethambutol . Immunomodulators ( except alpha interferon ) . Investigational drug ( except ddI , ddC , erythropoietin ) . Patients follow exclude : History allergy macrolide antimicrobial . Currently active therapy antimycobacterial drug list Exclusion Prior Medications . Currently active therapy carbamazepine theophylline , unless investigator agree carefully monitor blood level . Inability comply protocol judge near imminent death investigator . Active opportunistic infection . Requiring exclude concomitant medication . Prior Medication : Excluded least 4 week prior study entry : All antimycobacterial drug ( approve investigational ) exception isoniazid prophylaxis , discontinue Study Day minus 14 minus 7 .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>